Home
CONFRONT THE DEADLY THREAT OF mCRPC
RISING FROM WITHIN HIS BONES
mCRPC=Metastatic Castration-Resistant Prostate Cancer.
Prevalence and Pathology
MORE THAN 90% OF MEN WITH ADVANCED PROSTATE CANCER WILL DEVELOP BONE METASTASES2
Most men with advanced prostate cancer will experience a dangerous transformation in their disease when primary tumor cells invade the bone.1-3
SEER=Surveillance, Epidemiology, and End Results.
THE BONE SUPPORTS A VICIOUS MIGRATION OF TUMOR CELL METASTASES3-5
Prostate Cancer Preferentially Metastasizes to Bone via “Seed” and “Soil”3,4,6
Advanced prostate cancer is a disease that predominantly resides in the bones. The bone matrix is rich in factors that stimulate the growth of tumor cells and promote the cycle of metastases and bone pathology.3,4
Physical factors in the bone microenvironment, including a supportive vascular system, may also enhance tumor growth.4,6
Bone-metastatic cells migrate between distant sites (vs as separate waves from the primary tumor)5
- Bone metastases spawn additional metastatic sites
PC=Prostate Cancer.
Battle for Survival
IMPACT YOUR PATIENTS’ PROGNOSIS WHEN BONE METASTASES ARE FEWER, EARLY IN mCRPC7
Patients with ≥5 metastases have significantly reduced OS and progression-free survival vs patients with 1 to 4 metastases7
CI=Confidence Interval;
mCRPC=Metastatic Castration-Resistant Prostate Cancer;
OS=Overall Survival.
Monitoring Progression
VIGILANCE IN EVALUATING FOR DISEASE PROGRESSION IS IMPERATIVE8
There Are Multiple Ways to Monitor Disease Progression of Bone-Metastatic Disease
MONITORING MODALITIES | CLINICAL CONSIDERATIONS |
---|---|
PSA TESTING | |
RADIOGRAPHIC IMAGING | |
SYMPTOMS ASSESSMENT |
While testing for biochemical markers, such as PSA and ALP, and routine or scheduled radiographic scanning are important modalities in disease management, multiple symptoms can frequently indicate progression of metastatic disease.15-17
Therefore, symptom assessments and proactive discussions with patients about changes in symptoms can:
ALP=Alkaline Phosphatase;
PC=Prostate Cancer;
PSA=Prostate-Specific Antigen.
Evaluating Symptoms
PROACTIVE IDENTIFICATION OF CHANGES IN SYMPTOMS MAY SIGNAL THE NEED FOR A DIFFERENT CLINICAL APPROACH8,15,18,20
Monitoring Symptomatic Progression Is an Important Factor When Considering Your Clinical Approach in Patients With Advanced Prostate Cancer
PATIENTS WITH BONE-METASTATIC DISEASE EXHIBIT A RANGE OF SYMPTOMS BEYOND PAIN THAT EVOLVE OVER TIME
You May Think Your Patients With mCRPC in the Bone Don’t Have Symptoms, but Consider This:
68% OF MEN IGNORE THEIR SYMPTOMS14
Men with advanced prostate cancer are often burdened with symptoms that may cause significant changes in health-related quality of life (HRQOL), but don’t speak up about them. Therefore, a proactive discussion of changes in symptoms is crucial to help evaluate disease progression to determine therapeutic intervention.14,24,25
You can also download the Advanced Prostate Cancer Symptom Tracker below to help guide symptom discussions with your patients.
mCRPC=Metastatic Castration-Resistant Prostate Cancer.
Resources
RESOURCES
Click on the image to launch the file
To request printed copies of one or more of the resources below, visit our Contact a Bayer Representative page.
CAN WE BE DOING MORE TO CONFRONT THE DEADLY THREAT OF PROSTATE CANCER IN THE BONE?
Learn more about the fight against mCRPC in the bones
CONTACT A BAYER REPRESENTATIVE
mCRPC=Metastatic Castration-Resistant Prostate Cancer.